Defining the test-positive threshold to detect more than 50% of incident dementia led to a false-positive rate of 32% and a true to false positives ratio of 1 to 88 for CAIDE clinical, a false-positive rate of 24% and a true to false positives ratio of 1 to 66 for CAIDE–APOE-supplemented, a false-positive rate of 34% and a true to false positives ratio of 1 to 87 for BDSI, and a false-positive rate of 43% and a true to false positives ratio of 1 to 116 for ANU-ADRI. The gene discussed is APOE; the disease is dementia.